chufangao/CTO huggingface dataset:
Clinical trial NCT04880109: A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
Official title: A Phase 2, Double-blind, Placebo-controlled, Efficacy, and Safety Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
Sponsor: Aptabio Therapeutics, Inc. (INDIV)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Enrollment Challenges
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-20
Primary completion date: 2022-04-28
Completion date: 2022-04-28
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03818308: Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir
Official title: Multicenter Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir Fix Dose combination_The HepNet Acute HCV-V Study
Sponsor: Hannover Medical School (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 20.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-28
Primary completion date: 2021-06-08
Completion date: 2021-06-08
Plan to share individual participant data: NO
Clinical trial NCT05740280: iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects
Official title: iCP-NI - A Phase 1, Double Blind, Placebo Controlled, Single and Multiple Intravenous Infusion, Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects
Sponsor: Cellivery Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: The Sponsor has put the study on hold and will recommence in due time.
Enrollment: 64.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2023-01-19
Primary completion date: 2023-08-17
Completion date: 2023-08-17
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02864290: A Study to Evaluate Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Official title: A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of ASP1235 (AGS62P1) Given as Monotherapy in Subjects With Acute Myeloid Leukemia (AML)
Sponsor: Astellas Pharma Inc (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study was terminated due to lack of efficacy.
Enrollment: 43.0 (ACTUAL)
Number of arms: 6.0
Start date: 2016-11-10
Primary completion date: 2020-09-03
Completion date: 2020-09-03
Plan to share individual participant data: NO
IPD sharing description: Access to anonymized individual participant level data will not be provided for this trial as it meets one or more of the exceptions described on www.clinicalstudydatarequest.com under Sponsor Specific Details for Astellas.
Clinical trial NCT05191797: Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer
Official title: A Phase I/II Study of Bomedemstat Combined With Maintenance Immunotherapy for Patients With Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Closed per SRC Low Accrual Policy
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-04-11
Primary completion date: 2023-08-03
Completion date: 2024-04-05
Plan to share individual participant data: NO
Clinical trial NCT01571635: Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.
Official title: A Phase 2A, Open-label Dose Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With BETA(b)-THALASSEMIA.
Sponsor: Celgene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business objectives have changed
Enrollment: 46.0 (ACTUAL)
Number of arms: 6.0
Start date: 2012-10-10
Primary completion date: 2015-07-02
Completion date: 2022-05-24
Limitations and caveats: Sotatercept development in β-thalassemia indication was stopped and no further patients were enrolled after 1 mg/kg cohort was completed. Due to the early termination of the study and no enrollment of the Expansion Cohort, the primary analyses to determine the recommended dose (RD) and the secondary analysis of QoL change from baseline were not conducted.
Clinical trial NCT04001010: Safety and Efficacy of Inhaled Synthetic THC/CBD for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia
Official title: Safety and Efficacy of PPP011-kit for Improving Physical Functioning and for Modulating Cachexia Progression in Patients With Advanced Cancer and Associated Cachexia: a Randomized, Double Blind, Placebo Controlled, Parallel Group Study
Acronym: SERENITY
Sponsor: Tetra Bio-Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Study is postponed
Enrollment: 334.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2022-07-31
Primary completion date: 2023-07-31
Completion date: 2023-12-31
Clinical trial NCT03682692: ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)
Official title: ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD)
Sponsor: Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 560.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-01
Primary completion date: 2021-06-30
Completion date: 2022-03-31
Clinical trial NCT05316064: Reducing Abundance of Human Papilloma Virus in Women by Taking Probiotic
Official title: The Effects of Probiotic Against Reducing Abundance of Human Papilloma Virus (HPV) in Women
Sponsor: Universiti Sains Malaysia (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: funding problem
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-12-27
Primary completion date: 2023-11-28
Completion date: 2023-11-28
Plan to share individual participant data: NO
Clinical trial NCT04238390: Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection
Official title: A Multicentre, Parallel Group Open-label Randomised Controlled Non-Inferiority Phase 3 Trial, of Ceftolozane-tazobactam Versus Meropenem for Definitive Treatment of Bloodstream Infection Due to Extended-Spectrum Beta-Lactamase (ESBL) and AmpC-producing Enterobacterales
Acronym: MERINO III
Sponsor: The University of Queensland (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The decision to withdraw the study was made due to delayed logistics of the supply chain of ceftolozane-tazobactam along with the immense complexities of conducting clinical research felt because of the COVID-19 pandemic.
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-01-31
Primary completion date: 2024-06-30
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT03496207: A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)
Official title: A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Acronym: PULSAR
Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 106.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-06-13
Primary completion date: 2022-03-09
Completion date: 2022-03-09
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT05107856: PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies
Official title: A Phase 1, Open-Label, Multicenter, Dose Escalation Study of PRT1419 Injection as Monotherapy or in Combination With Azacitidine or Venetoclax in Patients With Relapsed/Refractory Myeloid or B-cell Malignancies
Sponsor: Prelude Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Company Decision
Enrollment: 21.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-03-22
Primary completion date: 2024-01-19
Completion date: 2024-01-19
Clinical trial NCT03591965: Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular Carcinoma (HCC) Subjects
Official title: An Open-label Phase 2 Trial of Dual TORC1/TORC2 Inhibitor ATG-008 in HBV+ Advanced Hepatocellular Carcinoma (HCC) Subjects Who Have Received at Least One Prior Line of Systemic Therapy (TORCH)
Sponsor: Antengene Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Based on the adjustment of clinical research and development strategy，sponsor decided to terminate the study
Enrollment: 73.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-07
Primary completion date: 2022-08-03
Completion date: 2022-08-03
Plan to share individual participant data: NO
Clinical trial NCT03631732: Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Official title: A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants
Acronym: BRAAVE 2020
Sponsor: Gilead Sciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 496.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-28
Primary completion date: 2019-08-12
Completion date: 2020-08-19
Baseline population: The Safety Analysis Set included all participants who were randomized into the study and had received at least 1 dose of study treatment (either B/F/TAF or baseline regimen on Day 1).
Plan to share individual participant data: YES
IPD sharing description: Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.
IPD time frame: 18 months after study completion
IPD access criteria: A secured external environment with username, password, and RSA code.
Clinical trial NCT03909165: Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years (MK-8616-169)
Official title: A Phase 4 Double-blinded, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy, Safety, and Pharmacokinetics of Sugammadex (MK-8616) for Reversal of Neuromuscular Blockade in Pediatric Participants Aged Birth to <2 Years
Sponsor: Merck Sharp & Dohme LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 145.0 (ACTUAL)
Number of arms: 5.0
Start date: 2019-07-23
Primary completion date: 2023-09-21
Completion date: 2023-09-21
Baseline population: The population used for Baseline Characteristics was the All Participants Allocated (Part A)/Randomized (Part B) Population, with the exception of the Protocol-defined Age Cohorts characteristic and Type of Neuromuscular Blocking Agent (NMBA) Characteristic, which were reported per protocol for the All Participants as Treated (APaT) population.
Plan to share individual participant data: YES
IPD sharing description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Clinical trial NCT05039944: SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies
Official title: A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Unresectable or Metastatic Digestive System Malignancies (Colorectal and Gastric Cancer)
Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Company research strategy adjustment
Enrollment: 7.0 (ACTUAL)
Number of arms: 6.0
Start date: 2021-11-30
Primary completion date: 2022-06-06
Completion date: 2022-06-06
Clinical trial NCT02700048: Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia
Official title: Intra-nasal Naloxone for Treatment of Impaired Awareness of Hypoglycemia
Sponsor: University of Minnesota (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: research grant for the trial was not funded
Enrollment: 11.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-30
Primary completion date: 2021-07-31
Completion date: 2021-07-31
Baseline population: the device failed so data was not collected and participants dropped prior to collecting baseline data
Clinical trial NCT03082729: Vascular Inflammation in Psoriasis - Apremilast
Official title: A Phase IV, Open Label Study of the Effects of Apremilast on Vascular Inflammation and Cardiometabolic Function in Psoriasis
Acronym: VIP-A
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 70.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-04-24
Primary completion date: 2021-08-17
Completion date: 2021-08-17
Limitations and caveats: The lack of placebo control; The number of biomarkers assessed may result in alpha error given the large number of pathways interrogated and thus the cardiometabolic biomarkers may be considered exploratory; Only surrogate markers evaluated and not actual clinical events.
Plan to share individual participant data: NO
Clinical trial NCT04249687: Treatment of Moderate to Severe Lateral Canthal Lines
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines
Acronym: READY-2
Sponsor: Galderma R&D (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 303.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-10
Primary completion date: 2020-09-25
Completion date: 2021-02-10
Clinical trial NCT02352753: Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of Denosumab in Children w/ OI
Official title: To Evaluate the Effect of Denosumab in Lumbar Spine Bone Mineral Density (BMD) Z-score at 12 Months, as Assessed by Dual-energy X-ray Absorptiometry (DXA), in Children 2 to 17 Years of Age (at the Time of Screening) on a 3-Month Dosing Regimen With OI
Acronym: OI
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was stopped earlier than planned due to safety concerns about high levels of calcium in the blood of the participants
Enrollment: 153.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-06-24
Primary completion date: 2022-03-26
Completion date: 2022-03-26
Baseline population: The full analysis set (FAS) included all participants who enrolled into the study.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Clinical trial NCT04264208: HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Official title: Evaluation of Patients With Low-Risk and Intermediate-Risk Prostate Cancer Scheduled for High-Dose Rate Brachytherapy Using 68-Ga-RM2 PET, 68Ga-PSMA-11 PET and Multi Parametric MRI
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of accrual due to pandemic and logistics
Enrollment: 4.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-02-05
Primary completion date: 2022-11-22
Completion date: 2022-12-14
Limitations and caveats: Early termination led to a small number of subjects analyzed
Plan to share individual participant data: NO
Clinical trial NCT03828929: Effect of IV Vitamin C, Thiamine, and Steroids on Mortality of Septic Shock
Official title: Effect of IV Vitamin C, Thiamine, and Steroids on Mortality of Septic Shock
Sponsor: New York Presbyterian Brooklyn Methodist Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Recent similar studies have been completed and published showing no benefit to the intervention.
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-15
Primary completion date: 2020-01-28
Completion date: 2020-02-04
Plan to share individual participant data: NO
Clinical trial NCT03259074: Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)
Official title: A Randomized, Partially-blinded Study of Secukinumab to Demonstrate Reduction of Radiographic Progression Versus GP2017 (Adalimumab Biosimilar) at 104 Weeks and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis
Acronym: SURPASS
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 859.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-11-30
Primary completion date: 2021-11-12
Completion date: 2021-11-29
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Clinical trial NCT03775421: An Upcoming Clinical Study to Measure the Safety and Impact of a Drug Called Macitentan in Teenage and Adult Fontan Patients.
Official title: Prospective, Multi-center, Single-arm, Open-label Long-term Study Assessing the Safety, Tolerability, and Effectiveness of Macitentan in Fontan-palliated Adult and Adolescent Subjects
Acronym: RUBATO OL
Sponsor: Actelion (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: As The RUBATO DB study (NCT03153137) did not show any benefit of treatment with macitentan in Fontan-palliated participants, the sponsor has decided to terminate the RUBATO OL study (NCT03775421). No new safety observations were made.
Enrollment: 112.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-04-11
Primary completion date: 2022-01-18
Completion date: 2022-01-18
Limitations and caveats: The study was stopped prematurely by the sponsor because the main double-blind (DB) study (AC-055H301; NCT03153137) did not meet the primary and secondary efficacy outcome measures.
Plan to share individual participant data: YES
IPD sharing description: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials\\transparency. As noted on this site, requests for access to the study data can be submitted through Yale open Access (YODA) Project site at yoda.yale.edu
Clinical trial NCT03432533: A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
Official title: A Randomized, Multicenter, Open-label, Parallel Group Study in Postmenopausal Women With Osteoporosis to Evaluate the Noninferiority of Subject-administered Romosozumab Via Autoinjector/Pen vs Healthcare Provider-administered Romosozumab Via Prefilled Syringe
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 283.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-02-06
Primary completion date: 2019-04-11
Completion date: 2020-01-08
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Clinical trial NCT04795141: ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis
Sponsor: Inmagene LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The sponsor's development strategy is adjusted.
Enrollment: 25.0 (ACTUAL)
Number of arms: 7.0
Start date: 2021-08-24
Primary completion date: 2022-07-11
Completion date: 2022-08-30